Comparative Pharmacology
Head-to-head clinical analysis: SEROSTIM versus ZORBTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROSTIM versus ZORBTIVE.
SEROSTIM vs ZORBTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
Recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, leading to increased IGF-1 production and promotion of linear growth.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
ZORBTIVE (somatropin) 0.006 mg/kg subcutaneously once daily for growth hormone deficiency in adults. Dose may be titrated based on clinical response and serum IGF-1 levels.
None Documented
None Documented
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Terminal elimination half-life of ZORBTIVE is approximately 2.5 hours after subcutaneous administration. For intravenous administration, the half-life is shorter at 0.6 hours. The longer subcutaneous half-life reflects sustained absorption from the injection site.
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
ZORBTIVE (somatropin) is eliminated primarily via the kidneys through glomerular filtration and tubular reabsorption. Approximately 70% of the dose is excreted renally as intact peptide, with 30% undergoing hepatic metabolism and biliary excretion. Fecal elimination accounts for less than 5%.
Category C
Category C
Growth Hormone
Growth Hormone